Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prevention

EISAI

Eisai slams Cancer Drugs Fund ‘black hole’

Will consider legal action to address the ‘unfair and inequitable situation’ for UK cancer patients

- PMLiVE

EMA: ‘business as usual’ – for now – after Brexit

And says it will be up to remaining EU members to decide on its future location

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Omnicom launches new DDB Health network

Will include its AgencyRx, Flashpoint, Synergy and DDB Health agencies

- PMLiVE

AZ, BMS and Boehringer among UK Prix Galien finalists

They join Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda

ABPI London offices

UK pharma HCP payment database goes live

Two-thirds of payments related to research and development work

ABPI London offices

Compliance cover-up sees Astellas suspended from ABPI

Code of Practice watchdog says it's one of the worst cases it has ever seen

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

- PMLiVE

UK pharma faces ‘immediate challenges’ following Brexit

Life science sector awaits fallout from vote to leave the European Union

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links